Ocugen vs Taysha Gene Therapies
OCGN and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCGN and TSHA compare
Taysha Gene Therapies is the larger company, worth 5.0 times as much as Ocugen ($1.3B against $262M).
Taysha Gene Therapies scores higher on the StockData Score (5 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCGN | TSHA |
|---|---|---|
| Size and price | ||
| Market cap | $262M | $1.3B |
| Share price | $0.773 | $4.06 |
| Change, 1 year | −37.7% | 1.2% |
| Change, 5 years | −88.0% | −68.0% |
| Beta (5Y) | −0.19 | 2.78 |
| Employees | 116 | 99 |
| StockData Score | ||
| Total score | 1 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 241× |
| P/B | – | 3.4× |
| FCF yield | −23.3% | −10.0% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −32.3% |
| Revenue growth, 5Y average | 152% | – |
| Profitability | ||
| Operating margin | – | −2792% |
| Net margin | – | −2728% |
| FCF margin | – | −2417% |
| Return on equity | – | −47.1% |
| Financial health | ||
| Debt / equity | – | 0.13 |
| Interest coverage | −8.2× (better) | −3646.6× |
| Current ratio | 0.80 | 17.76 (better) |
| Altman Z-score | −6.06 | 7.21 (better) |
| Piotroski F-score | 0 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 42.8% | 91.9% |
| Held by insiders | 2.4% | 10.7% |
| Insider net buying, 12 months | −$1.1M (better) | −$6.1M |
| Short interest, % of float | 32.5% | 18.4% |
Go deeper
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
- TSHA stock overview
- TSHA income statement
- TSHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.